Tinnitus News and Research

Latest Tinnitus News and Research

Microsurgical technique effective in removing acoustic tumors

Surgery to remove tumors under the brain known as acoustic neuromas produces favorable outcomes in the "vast majority" of patients, according to one of the largest studies of its kind.

8 Dec 2010

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

PAXX100 audio device improves quality of life of people with tinnitus

Tinnitus Laboratory today announced the results of a clinical study that shows significant improvements from the use of PAXX100, a customized audio device for tinnitus management designed for long-term reduction of tinnitus perception.

13 Oct 2010

Pycnogenol effective in relieving tinnitus symptoms: Study

More than 50 million Americans will experience some degree of tinnitus in their lifetime, according to the American Tinnitus Association. Tinnitus is a hearing condition that causes the constant misperception of sound, including hissing, ringing and rushing noises. A study recently published in Panminerva Medica reveals that Pycnogenol (pic-noj-en-all), an antioxidant plant extract derived from the bark of the French maritime pine tree, is effective in relieving tinnitus symptoms by improving blood flow in the inner ear.

13 Oct 2010

Researchers find significant difference between prevalence of tinnitus among elderly people

Tinnitus is common among elderly Nigerians and associated with treatable health conditions like otitis media, rhinosinusitis, head injury and hypertension, according to new research published in the October 2010 issue of Otolaryngology - Head and Neck Surgery.

8 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

Anticancer drug Cisplatin induces side effects

Cisplatin, an anticancer drug widely used for treating various types of tumor, can induce side effects in the short term. A team of scientists, mostly from CNRS and the Université de Nice has provided first in vitro evidence that this antitumor agent modifies the sensitivity of cellular pressure sensors. This completely novel mechanism could help to elucidate certain neurological side effects of cisplatin hitherto unexplained.

6 Oct 2010

Personal listening devices can impair hearing: Study

Personal listening devices like iPods have become increasingly popular among young and not so young people in recent years. But music played through headphones too loud or too long might pose a significant risk to hearing, according to a 24-year study of adolescent girls.

31 Aug 2010

Otonomy announces closing of $38.5 million Series B financing

Otonomy, Inc. announced today that it has closed a $38.5 million Series B financing co-led by Novo Ventures and RiverVest Venture Partners, and joined by Domain Associates and TPG Biotech. This financing is incremental to the $10 million Series A closed with Avalon Ventures in June 2010. Avalon also participated in the Series B round.

30 Aug 2010

UT Dallas receives grant from NIH to investigate nerve stimulation for tinnitus

The NIH has granted a University of Texas at Dallas researcher and a university-affiliated biomedical firm $1.7 million to investigate whether nerve stimulation offers a long-term cure for tinnitus.

12 Aug 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals is pleased to announce the launch of Neptazane (Methazolamide) 25 mg and 50 mg tablets. Both strengths are available in 90 count bottles.

3 Jul 2010

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New long term data showed that Vimpat- (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents and those that act on non-sodium channel-targets.

30 Jun 2010

Relative importance of genetic factors is low in tinnitus, says new research

The relative importance of genetic factors in tinnitus is low, according to new research from the Norwegian Institute of Public Health. This is the first large population-based study to measure the heritability of tinnitus.

21 Apr 2010

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.

25 Feb 2010

FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients

Otonomy, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of OTO-104 in patients with Meniere's disease, a debilitating disorder of the inner ear affecting balance and hearing.

17 Feb 2010

Tinnitus not a highly inherited condition, says study

Tinnitus, or ringing in the ears, does not appear to be a highly inherited condition (i.e., does not pass frequently from parents to offspring), according to a report in the February issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.

16 Feb 2010

Low frequency therapy for temporary tinnitus: Student research project evolves into web-based company

In 2009 a student research project investigating a low frequency therapy for temporary tinnitus was joint runner-up in the 2009 BT Young Scientist and Technology Exhibition, held in Dublin, Ireland. The student research project which has now evolved into a web-based company, Restored Hearing (www.restoredhearing.ie) was one of the companies which showcased recently at the 2010 exhibition.

5 Feb 2010

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Flexion Therapeutics today announced agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and gaining investment from the world’s biggest pharmaceutical company.

29 Jan 2010

Caffeine abstinence: An ineffective and potentially distressing tinnitus therapy

New research has found giving up caffeine does not relieve tinnitus and acute caffeine withdrawal might add to the problem. This is the first study of its kind to look at the effect of caffeine consumption on tinnitus.

13 Jan 2010

Tinnitus News and Research

Latest Tinnitus News and Research

Microsurgical technique effective in removing acoustic tumors

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

PAXX100 audio device improves quality of life of people with tinnitus

Pycnogenol effective in relieving tinnitus symptoms: Study

Researchers find significant difference between prevalence of tinnitus among elderly people

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Anticancer drug Cisplatin induces side effects

Personal listening devices can impair hearing: Study

Otonomy announces closing of $38.5 million Series B financing

UT Dallas receives grant from NIH to investigate nerve stimulation for tinnitus

Xeomin receives FDA approval for treatment of cervical dystonia

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

Relative importance of genetic factors is low in tinnitus, says new research

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients

Tinnitus not a highly inherited condition, says study

Low frequency therapy for temporary tinnitus: Student research project evolves into web-based company

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Caffeine abstinence: An ineffective and potentially distressing tinnitus therapy

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Tinnitus News and Research

Latest Tinnitus News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in